A carregar...
CMET-21. TOLERANCE AND OUTCOMES OF STEREOTACTIC RADIOSURGERY COMBINED WITH ANTI-PD1 (PEMBROLIZUMAB) FOR MELANOMA BRAIN METASTASES
Anti-PD1 antibodies are currently the first-line treatment for patients with metastatic BRAF wild- type melanoma, alone or combined with the anti-CTLA4 mAb, ipilimumab. To date, data on safety and the outcomes of patients treated with the anti-PD1 mAbs, pembrolizumab (PB) or nivolumab, combined with...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692939/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.169 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|